Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC).Materials and methods This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1-5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT.Results Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4-91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5-19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8-25.8 months). One-year systemic treatment-free survival was 72.1%.Conclusion SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Self-citation
Cited by
Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., Mottet, N., Shore, N., Small, E., Smith, M., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.018 · Cited by 166
Self-citationGillessen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K. S., James, N. D., Shore, N. D., Small, E. J., Smith, M. R., Sweeney, C. J., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.017 · Cited by 179
Self-citationFrancolini, G., Allegra, A. G., Detti, B., Di Cataldo, V., Caini, S., Bruni, A., Ingrosso, G., D'Angelillo, R. M., Alitto, A. R., Augugliaro, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00985 · Cited by 139
“Despite several retrospective reports about its use in mCRPC, 9,10 currently limited prospective evidence exists on a combined approach of SBRT with ARTA in patients with mCRPC. Zhang et al published a phase II trial including 89 patients with oligometastatic CRPC (oligo-mCRPC) treated on 128…”
BackgroundSelf-citationDeek, M. P., Taparra, K., Phillips, R., Velho, P. I., Gao, R. W., Deville, C., Song, D. Y., Greco, S., Carducci, M., Eisenberger, M., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2020.05.004 · Cited by 96
Radiotherapy of oligometastatic prostate cancer: a systematic review
Rogowski, P., Roach, M., Schmidt-Hegemann, N.-S., Trapp, C., von Bestenbostel, R., Shi, R., Büchner, A., Stief, C. G., Belka, C., & Li, M. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01776-8 · Cited by 91
Metadata
- Authors
- Triggiani, L., Mazzola, R., Magrini, S. M., Ingrosso, G., Borghetti, P., Trippa, F., Lancia, A., Detti, B., Francolini, G., Matrone, F., Bortolus, R., Fanetti, G., Maranzano, E., Pasqualetti, F., Paiar, F., Bonù, M. L., Magli, A., Bruni, A., Mazzeo, E., Franzese, C., Scorsetti, M., Alongi, F., Jereczek-Fossa, B. A., Ost, P., & Buglione, M.
- Affiliations
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Sacro Cuore Don Calabria (IT)
- Policlinico Tor Vergata (IT)
- Azienda Ospedaliera S.Maria (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Centro di Riferimento Oncologico (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- University of Udine (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Humanitas University (IT)
- Ghent University Hospital (BE)
- Corresponding author
- Mazzola, Rosario
- ORCID
- Triggiani, Luca
- Mazzola, Rosario
- Magrini, Stefano Maria
- Ingrosso, Gianluca
- Borghetti, Paolo
- Trippa, Fabio
- Lancia, Andrea
- Detti, Beatrice
- Francolini, Giulio
- Matrone, Fabio
- Bortolus, Roberto
- Fanetti, Giuseppe
- Maranzano, Ernesto
- Pasqualetti, Francesco
- Paiar, Fabiola
- Bonù, Marco Lorenzo
- Magli, Alessandro
- Bruni, Alessio
- Franzese, Ciro
- Scorsetti, Marta
- Alongi, Filippo
- Ost, Piet
- Buglione, Michela
- Venue
- World Journal of Urology
- Published
- 2019-03-11
- Volume
- 37
- Issue
- 12
- Pages
- 2631-2637
- ISSN
- 0724-4983 (ISSN-L)
- 1433-8726
- OpenAlex
- W2921789984
- Cited by
- 96
- References
- 27
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 25 · 2020: 13 · 2019: 8
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- World Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- stereotactic body radiotherapy, metastasis-directed radiotherapy, bone metastasis, lymph node metastasis, androgen deprivation therapy
- MeSH terms
- Aged, Aged, 80 and over, Humans, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Radiosurgery, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. https://app.cochat.ai/papers/10.1007/s00345-019-02717-7
- The paper
- Triggiani, L., Mazzola, R., Magrini, S. M., Ingrosso, G., Borghetti, P., Trippa, F., Lancia, A., Detti, B., Francolini, G., Matrone, F., Bortolus, R., Fanetti, G., Maranzano, E., Pasqualetti, F., Paiar, F., Bonù, M. L., Magli, A., Bruni, A., Mazzeo, E., . . . Buglione, M. (2019). Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology. https://doi.org/10.1007/s00345-019-02717-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.